Zonisamide

Overview

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K i s of 35.2 and 20.6 nM for hCA II and hCA V , respectively. Zonisamide exerts neuroprotective effects through anti- apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1 , thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Carbonic Anhydrase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-B0124
• CAS No.: 68291-97-4
• Molecular Formula: C8H8N2O3S
• Molecular Weight: 212.23
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (9.80 mM); Clear solution
• Availability: In-stock

Source

Original product source